Kezar Life Sciences

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

Our mission is to pioneer and develop novel therapeutic solutions to improve the lives of patients with systemic autoimmune diseases.

We envision a better future in which innovative, life-changing solutions are developed to reduce the burden of systemic autoimmune diseases.

Kezar Life Sciences has received numerous awards, including the 2020 Fierce Biotech Award for Best Use of Technology in Clinical Trials and the 2019 Technology in Innovation Award from BioSpace. We are also proud partners of the Lupus Research Alliance and the Lupus Foundation of America.